Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Hatch/Waxman Reinterpretation Underpins Change In 30-Month Stay Policy

Oct 28 2002

• By The Tan Sheet

Related Content

FDA Patent Listing Criteria Allow Polymorph, Product-By-Process Claims

Oct 28 2002

FTC Backs Single 30-Month Stay On Generic Approvals In Patent Litigation

Aug 05 2002

Additional Topics

OTC Drugs Consumer

More from Archive

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window